One more takeaway from this interview was the 4th bullet point- 3 cohorts of dose expansion have completed without any DLTs or safety concerns.
I also liked 3 bullet points on the anatomical, molecular and biochemical responses which wraps up the conclusions nicely IMO:
One more takeaway from this interview was the 4th bullet point-...
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$7.39 |
Change
0.160(2.21%) |
Mkt cap ! $2.305B | |||
| Open | High | Low | Value | Volume |
| $7.00 | $7.44 | $6.96 | $4.961M | 678.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 15 | 2734 | $7.39 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $7.41 | 1143 | 15 |
View Market Depth
| Last trade - 12.02pm 09/09/2024 (20 minute delay) ? |
| CU6 (ASX) Chart |